Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mireille Goetghebeur

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
Pharmacoeconomics|March 22, 2017
Authors' Reply to Gandjour: "Can the EVIDEM Framework Tackle Issues Raised by Evaluating Treatments for Rare Diseases: Analysis of Issues and Policies, and Context-Specific Adaptation"Monika Wagner, Mireille Goetghebeur
International Journal of Health Policy and Management|July 3, 2020
Deliberative Processes by Health Technology Assessment Agencies: A Reflection on Legitimacy, Values and Patient and Public Involvement Comment on "Use of Evidence-informed Deliberative Processes by Health Technology Assessment Agencies Around the Globe"Mireille Goetghebeur, Marjo Cellier
The Canadian Journal of Infectious Diseases & Medical Microbiology = Journal Canadien Des Maladies Infectieuses Et De La Microbiologie Medicale|May 24, 2014
Clinical and economic consequences of vancomycin and fidaxomicin for the treatment of Clostridium difficile infection in CanadaMonika Wagner, Louis Lavoie, Mireille Goetghebeur
Lancet (London, England)|September 11, 2018
The art of priority settingMireille Goetghebeur, Hector Castro-Jaramillo, Rob Baltussen, et al.
The Canadian Journal of Infectious Diseases & Medical Microbiology = Journal Canadien Des Maladies Infectieuses Et De La Microbiologie Medicale|October 17, 2008
Methicillin-resistant Staphylococcus aureus: A public health issue with economic consequencesMireille Goetghebeur, Pierre-Alexandre Landry, Donald Han, et al.
International Journal of Technology Assessment in Health Care|October 4, 2016
TESTING MULTI-CRITERIA DECISION ANALYSIS FOR MORE TRANSPARENT RESOURCE-ALLOCATION DECISION MAKING IN COLOMBIAHector Eduardo Castro Jaramillo, Mireille Goetghebeur, Ornella Moreno-Mattar
Pharmacoeconomics|November 9, 2015
Can the EVIDEM Framework Tackle Issues Raised by Evaluating Treatments for Rare Diseases: Analysis of Issues and Policies, and Context-Specific AdaptationMonika Wagner, Hanane Khoury, Jacob Willet, et al.
Health Research Policy and Systems|May 1, 2015
Exploring the perspectives and preferences for HTA across German healthcare stakeholders using a multi-criteria assessment of a pulmonary heart sensor as a case studyPhilip Wahlster, Mireille Goetghebeur, Sandra Schaller, et al.
BMC Health Services Research|July 9, 2015
Balancing costs and benefits at different stages of medical innovation: a systematic review of Multi-criteria decision analysis (MCDA)Philip Wahlster, Mireille Goetghebeur, Christine Kriza, et al.
Cost Effectiveness and Resource Allocation : C/E|April 24, 2015
Does technique matter; a pilot study exploring weighting techniques for a multi-criteria decision support frameworkJanine van Til, Catharina Groothuis-Oudshoorn, Marijke Lieferink, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Pharmacoeconomics|March 22, 2017
Authors' Reply to Gandjour: "Can the EVIDEM Framework Tackle Issues Raised by Evaluating Treatments for Rare Diseases: Analysis of Issues and Policies, and Context-Specific Adaptation"Monika Wagner, Mireille Goetghebeur
International Journal of Health Policy and Management|July 3, 2020
Deliberative Processes by Health Technology Assessment Agencies: A Reflection on Legitimacy, Values and Patient and Public Involvement Comment on "Use of Evidence-informed Deliberative Processes by Health Technology Assessment Agencies Around the Globe"Mireille Goetghebeur, Marjo Cellier
The Canadian Journal of Infectious Diseases & Medical Microbiology = Journal Canadien Des Maladies Infectieuses Et De La Microbiologie Medicale|May 24, 2014
Clinical and economic consequences of vancomycin and fidaxomicin for the treatment of Clostridium difficile infection in CanadaMonika Wagner, Louis Lavoie, Mireille Goetghebeur
Lancet (London, England)|September 11, 2018
The art of priority settingMireille Goetghebeur, Hector Castro-Jaramillo, Rob Baltussen, et al.
The Canadian Journal of Infectious Diseases & Medical Microbiology = Journal Canadien Des Maladies Infectieuses Et De La Microbiologie Medicale|October 17, 2008
Methicillin-resistant Staphylococcus aureus: A public health issue with economic consequencesMireille Goetghebeur, Pierre-Alexandre Landry, Donald Han, et al.
International Journal of Technology Assessment in Health Care|October 4, 2016
TESTING MULTI-CRITERIA DECISION ANALYSIS FOR MORE TRANSPARENT RESOURCE-ALLOCATION DECISION MAKING IN COLOMBIAHector Eduardo Castro Jaramillo, Mireille Goetghebeur, Ornella Moreno-Mattar
Pharmacoeconomics|November 9, 2015
Can the EVIDEM Framework Tackle Issues Raised by Evaluating Treatments for Rare Diseases: Analysis of Issues and Policies, and Context-Specific AdaptationMonika Wagner, Hanane Khoury, Jacob Willet, et al.
Health Research Policy and Systems|May 1, 2015
Exploring the perspectives and preferences for HTA across German healthcare stakeholders using a multi-criteria assessment of a pulmonary heart sensor as a case studyPhilip Wahlster, Mireille Goetghebeur, Sandra Schaller, et al.
BMC Health Services Research|July 9, 2015
Balancing costs and benefits at different stages of medical innovation: a systematic review of Multi-criteria decision analysis (MCDA)Philip Wahlster, Mireille Goetghebeur, Christine Kriza, et al.
Cost Effectiveness and Resource Allocation : C/E|April 24, 2015
Does technique matter; a pilot study exploring weighting techniques for a multi-criteria decision support frameworkJanine van Til, Catharina Groothuis-Oudshoorn, Marijke Lieferink, et al.
Pageof 2